Docetaxel as Single-Agent Treatment in Elderly Patients with Advanced Breast Cancer

Lorenzo, Isabel Lorenzo; Constenla, Manuel; Palacios, Patricia; García-Arroyo, Francisco R.; Fernández, Irene Mirón; Campos, Begoña; Salgado, L.; Carrete, N.

doi:10.2165/00044011-200525040-00004

Cited by 6 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taxanes have shown encouraging anti-tumor activity against various cancers, including gastric cancer [15,16,17]. Compared with a schedule of once every 3 weeks, weekly paclitaxel has shown milder toxicity and increased dose intensity in ovarian, lung and gastric cancer, and especially for heavily pretreated patients [17,18].…”

Section: Introductionmentioning

confidence: 99%

A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status

Rha

Jeung

et al. 2009

Oncology

View full text Add to dashboard Cite

Purpose: We investigated the efficacy and safety of weekly paclitaxel monotherapy in previously treated patients with advanced gastric cancer (AGC) and poor performance status (PS) according to the Eastern Cooperative Oncology Group (ECOG). Patients and Methods: Patients with evaluable disease who failed at least one previous chemotherapy and had a PS of 2–3, received paclitaxel 70 mg/m² on days 1, 8 and 15 every 4 weeks. Results: The median overall survival (OS) was 5.5 months (95% confidence interval, CI, 3.3–7.8) and progression-free survival was 2.1 months (95% CI, 1.2–3.0). The overall response rate was 3.8% and the disease control rate was 25.0%. Treatment-related toxicities were tolerable. OS was 7.1 (95% CI, 5.4–9.5) and 3.7 months (95% CI, 2.1–5.3) for patients with PS-ECOG 2 and 3, respectively (p < 0.001). When evaluated according to the previous treatment, OS was 5.1 (95% CI, 3.3–7.0) and 6.5 months (95% CI, 3.8–9.3) for patients receiving two and three or more lines of treatment, respectively (p = 0.815). With multivariate analysis, PS was a significant factor for OS. Conclusion: Survival in patients treated with weekly paclitaxel monotherapy was comparable to other second- or third-line chemotherapies for AGC, with acceptable toxicities in previously treated patients with poor PS.

show abstract

Section: Introductionmentioning

confidence: 99%

A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status

Rha

Jeung

et al. 2009

Oncology

View full text Add to dashboard Cite

show abstract

Chemotherapy treatment for older women with metastatic breast cancer: What is the evidence?

Debled

Bellera

Donamaria

et al. 2011

Cancer Treatment Reviews

View full text Add to dashboard Cite

Taxanes in the elderly patient with metastatic breast cancer

Yardley

2015

BCTT

View full text Add to dashboard Cite

More than 40% of all breast cancer cases are diagnosed in patients aged ≥65 years, accounting for an ever-increasing disease burden in the elderly. Historically, however, this growing population of breast cancer patients has been underrepresented in clinical trials, resulting in a paucity of data that clinicians can reference in making treatment decisions for their older patients. A consequence may be the undertreatment of elderly patients, who have the highest incidence of breast cancer. However, subgroup analyses of elderly patients in multiple early-Phase (I or II) studies and a handful of small studies with elderly-specific populations have suggested that older patients may experience similar benefit from cancer therapy as younger patients with otherwise similar baseline characteristics. Although steps should be taken to avoid undertreating older patients, a balance must be achieved to avoid overtreatment. Guidelines have been released detailing recommendations for the treatment of elderly breast cancer patients, including a discussion of various geriatric assessments that might aid physicians in selecting patients appropriate for recommended treatment options. Chemotherapy remains a key component of treatment regimens for many older patients. However, the benefit of some agents may be limited by tolerability issues. Taxanes, one of the most established classes of chemotherapy for breast cancer, are known to be highly active and efficacious and to have well-characterized safety profiles. This review discusses factors that influence treatment choices for elderly patients with metastatic breast cancer, and then focuses on clinical data for taxanes in this patient population.

show abstract

Docetaxel as Single-Agent Treatment in Elderly Patients with Advanced Breast Cancer

Abstract: Docetaxel as a single agent is active in elderly patients with advanced breast cancer. The use of prophylactic G-CSF allowed the administration of high doses of docetaxel with minimal myelosuppression.

Cited by 6 publications

References 22 publications

A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status

A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status

Chemotherapy treatment for older women with metastatic breast cancer: What is the evidence?

Taxanes in the elderly patient with metastatic breast cancer

Contact Info

Product

Resources

About